Observational studyBMC cancer2026
Observational study of trastuzumab biosimilar in patients with HER2-positive breast cancer under routine clinical practice conditions in Morocco.
Observational study in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTrastuzumab, a recombinant humanized monoclonal antibody has demonstrated clinical benefits in women with human epidermal growth factor receptor type 2 (HER2)-positive breast cancer in early and metastatic disease settings. However, real-world data on trastuzumab biosimilars are limited. The primary aim of the HERLife study was to confirm the tolerance of trastuzumab biosimilar from Mylan (Hertraz) in terms of cardiac safety in HER2-positive patients diagnosed with early or metastatic breast cancers under routine clinical practice in Morocco.
methodsThis was a prospective, non-interventional, multi-center, 12-month follow-up study in adult patients with HER2-positive breast cancer treated with trastuzumab biosimilar. Patients aged ≥ 18 years and with left ventricular ejection fraction (LVEF) ≥ 50% were included. Data on cardiac events, serious or unexpected adverse events (AEs), drug interactions cases, chemotherapy protocols, and response to treatment were collected.
resultsIn total, 99 patients were included (early breast cancer, n = 70; metastatic breast cancer, n = 29). The median (range) age was 53 (29–76) years. Switching from trastuzumab reference to trastuzumab biosimilar was observed in 32 (32.3%) patients in the overall population, including 45.0% of metastatic breast cancer and 27.0% of early breast cancer patients. Pertuzumab was used in combination with trastuzumab biosimilar in 41.4% and 19.0% of patients in the metastatic and neoadjuvant settings, respectively. Two patients (2.0%) developed an expected AE of a non-significant fall in LVEF, requiring temporary discontinuation of trastuzumab biosimilar for three weeks. No other trastuzumab-related AEs or drug interactions were reported. Four patients (26.7%) had a pathological complete response in the neoadjuvant group (n = 15) over the 12-month follow-up period.
conclusionsTrastuzumab biosimilar was found to have acceptable cardiac safety and a comparable profile of efficacy in HER2-positive breast cancer patients in Morocco.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.